語系:
繁體中文
English
說明(常見問題)
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Benefit-Risk Assessment of Medicines...
~
Leong, James.
Benefit-Risk Assessment of Medicines = The Development and Application of a Universal Framework for Decision-Making and Effective Communication /
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
正題名/作者:
Benefit-Risk Assessment of Medicines/ by James Leong, Sam Salek, Stuart Walker.
其他題名:
The Development and Application of a Universal Framework for Decision-Making and Effective Communication /
作者:
Leong, James.
其他作者:
Salek, Sam.
面頁冊數:
XIII, 317 p. 163 illus., 138 illus. in color.online resource. :
Contained By:
Springer Nature eBook
標題:
Pharmacy. -
電子資源:
https://doi.org/10.1007/978-3-319-15805-1
ISBN:
9783319158051
Benefit-Risk Assessment of Medicines = The Development and Application of a Universal Framework for Decision-Making and Effective Communication /
Leong, James.
Benefit-Risk Assessment of Medicines
The Development and Application of a Universal Framework for Decision-Making and Effective Communication /[electronic resource] :by James Leong, Sam Salek, Stuart Walker. - 1st ed. 2015. - XIII, 317 p. 163 illus., 138 illus. in color.online resource.
Prologue -- Preface -- Overview -- Approaches to utilising decision-making framework -- Benefit-risk assessment of medicines by pharmaceutical companies and regulatory authorities -- Development of a universal benefit-risk framework and template -- Implementation of the benefit-risk assessment template by mature agencies -- Implementation of the benefit- risk summary template by a maturing agency: A case study -- Communicating benefit-risk decisions by US FDA, EMA, TGA and Health Canada -- Conclusions and future directions -- References.
This book proposes and investigates a universal framework, and accompanying documentation system, to facilitate and catalogue benefit-risk decisions; a valuable addition to the benefit-risk toolbox. Over the past decade, pharmaceutical companies and regulatory agencies have been reviewing the benefit-risk assessment of medicines with a view to developing a structured, systematic, standardized approach. Examining the evaluation of such an approach by several mature regulatory authorities ensures that the reader gains a unique insight into the ongoing debate in this area. The field of benefit-risk assessment continues to evolve at a rapid pace due to political and societal pressure, as is reflected in the recent FDA PUDFA agreement as well as in the EMA 2015 Roadmap. Rather than provide a comprehensive snap-shot of this constantly changing environment, this book evaluates selected current approaches to benefit-risk assessment. The strengths and weaknesses of publicly available documents in communicating benefit-risk decisions to stakeholders are reviewed, and these evaluations are used to inform development of a prospective framework that could be used to harmonise procedures globally.
ISBN: 9783319158051
Standard No.: 10.1007/978-3-319-15805-1doiSubjects--Topical Terms:
582411
Pharmacy.
LC Class. No.: RS1-441
Dewey Class. No.: 353.998
Benefit-Risk Assessment of Medicines = The Development and Application of a Universal Framework for Decision-Making and Effective Communication /
LDR
:03182nam a22003975i 4500
001
969017
003
DE-He213
005
20200706162641.0
007
cr nn 008mamaa
008
201211s2015 gw | s |||| 0|eng d
020
$a
9783319158051
$9
978-3-319-15805-1
024
7
$a
10.1007/978-3-319-15805-1
$2
doi
035
$a
978-3-319-15805-1
050
4
$a
RS1-441
072
7
$a
MMG
$2
bicssc
072
7
$a
MED071000
$2
bisacsh
072
7
$a
MKG
$2
thema
082
0 4
$a
353.998
$2
23
100
1
$a
Leong, James.
$e
author.
$4
aut
$4
http://id.loc.gov/vocabulary/relators/aut
$3
1264607
245
1 0
$a
Benefit-Risk Assessment of Medicines
$h
[electronic resource] :
$b
The Development and Application of a Universal Framework for Decision-Making and Effective Communication /
$c
by James Leong, Sam Salek, Stuart Walker.
250
$a
1st ed. 2015.
264
1
$a
Cham :
$b
Springer International Publishing :
$b
Imprint: Adis,
$c
2015.
300
$a
XIII, 317 p. 163 illus., 138 illus. in color.
$b
online resource.
336
$a
text
$b
txt
$2
rdacontent
337
$a
computer
$b
c
$2
rdamedia
338
$a
online resource
$b
cr
$2
rdacarrier
347
$a
text file
$b
PDF
$2
rda
505
0
$a
Prologue -- Preface -- Overview -- Approaches to utilising decision-making framework -- Benefit-risk assessment of medicines by pharmaceutical companies and regulatory authorities -- Development of a universal benefit-risk framework and template -- Implementation of the benefit-risk assessment template by mature agencies -- Implementation of the benefit- risk summary template by a maturing agency: A case study -- Communicating benefit-risk decisions by US FDA, EMA, TGA and Health Canada -- Conclusions and future directions -- References.
520
$a
This book proposes and investigates a universal framework, and accompanying documentation system, to facilitate and catalogue benefit-risk decisions; a valuable addition to the benefit-risk toolbox. Over the past decade, pharmaceutical companies and regulatory agencies have been reviewing the benefit-risk assessment of medicines with a view to developing a structured, systematic, standardized approach. Examining the evaluation of such an approach by several mature regulatory authorities ensures that the reader gains a unique insight into the ongoing debate in this area. The field of benefit-risk assessment continues to evolve at a rapid pace due to political and societal pressure, as is reflected in the recent FDA PUDFA agreement as well as in the EMA 2015 Roadmap. Rather than provide a comprehensive snap-shot of this constantly changing environment, this book evaluates selected current approaches to benefit-risk assessment. The strengths and weaknesses of publicly available documents in communicating benefit-risk decisions to stakeholders are reviewed, and these evaluations are used to inform development of a prospective framework that could be used to harmonise procedures globally.
650
0
$a
Pharmacy.
$3
582411
650
0
$a
Medical research.
$2
bicssc
$3
809476
650
1 4
$a
Drug Safety and Pharmacovigilance.
$3
1064651
650
2 4
$a
Quality of Life Research.
$3
671860
700
1
$a
Salek, Sam.
$4
aut
$4
http://id.loc.gov/vocabulary/relators/aut
$3
1208851
700
1
$a
Walker, Stuart.
$e
author.
$4
aut
$4
http://id.loc.gov/vocabulary/relators/aut
$3
1258349
710
2
$a
SpringerLink (Online service)
$3
593884
773
0
$t
Springer Nature eBook
776
0 8
$i
Printed edition:
$z
9783319158068
776
0 8
$i
Printed edition:
$z
9783319158044
776
0 8
$i
Printed edition:
$z
9783319367675
856
4 0
$u
https://doi.org/10.1007/978-3-319-15805-1
912
$a
ZDB-2-SME
912
$a
ZDB-2-SXM
950
$a
Medicine (SpringerNature-11650)
950
$a
Medicine (R0) (SpringerNature-43714)
筆 0 讀者評論
多媒體
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼[密碼必須為2種組合(英文和數字)及長度為10碼以上]
登入